Clinical phenotype in systemic mastocytosis (SM) is markedly variable, which complicates prognostication and decision making regarding the choice and timing of therapy. In a retrospective study of 342 consecutive adult patients with SM seen at the 
Introduction
Mastocytosis is a heterogenous disorder characterized by the abnormal growth and accumulation of morphologically and immunophenotypically abnormal mast cells (MCs) in one or more organs. The clinical presentation of mastocytosis is diverse, and many patients do not fit the classical description -namely, a variably long history of urticaria pigmentosa (UP), followed by the insidious onset of flushing, cramping abdominal pain, diarrhea, bone pain, and hepatosplenomegaly. [1] [2] [3] [4] Unlike pediatric cases, most adults with UP-like skin lesions have systemic disease (i.e. systemic mastocytosis [SM] ) at presentation, a condition generally confirmed by means of a bone marrow (BM) biopsy. 5 MCs are derived from CD34+/KIT+ pluripotent hematopoietic cells in the bone marrow; 6 its neoplastic counterparts are morphologically atypical (spindled shape, hypogranular cytoplasm, nuclear atypia), 7, 8 and express abnormal cell surface markers (CD25 and/or CD2). 9, 10 Most, if not all, adult mastocytosis patients carry gain-of-function KIT receptor mutations, most commonly D816V in the tyrosine kinase domain.
11,12
The natural history of SM, ranging from indolent forms spanning years to more aggressive subtypes that rapidly progress to leukemia, complicates decision making regarding the choice of therapeutic modalities and timing of intervention. In 1988, Mayo
Clinic investigators proposed a classification wherein SM patients were grouped into the following subtypes: (i) indolent SM (ISM); (ii) SM with associated hematological disorders (SM-AHD); (iii) aggressive SM (ASM); and (iv) mast cell leukemia (MCL), based on distinct clinicopathologic features. 2 In 2001, the World Health Organization (WHO) formalized the above classification and further refined it by incorporating recent advances in SM, including identification of KITD816V, aberrant expression of cell
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From surface markers on neoplastic MCs, and elevated tryptase level in serum. 13 Although the WHO proposal represents a major advance in identifying clinically distinct SM subgroups based on defined criteria and, consequently, has been widely adopted in clinical practice, it has hitherto not been validated in a large cohort of SM patients.
The aim of the current study was: (i) to describe the clinical and laboratory features at presentation in a large cohort of SM patients; (ii) to describe the risk of leukemic transformation and estimate mortality of SM patients within the context of the current WHO classification; (iii) to estimate life expectancy relative to age-and gendermatched controls as a basis for clinical decision making; (iv) to evaluate prognostic relevance of the WHO subclassification of SM, and to identify additional clinical, laboratory, and/or bone marrow histological features that have prognostic value; and (v) evaluate the prevalence and prognostic relevance of KITD816V and JAK2V617F mutations in this cohort.
Methods

Patients:
The current study was approved by the Mayo Clinic institutional review board.
All patients provided informed authorization for use of their medical records for research purposes, and research was carried out according to the principles of the Declaration of and/or CD25 expression on BM MC was studied by immunohistochemistry and/or flow cytometry in a subset of cases (n=84; 25%), as previously described.
10 Cytogenetic analysis was performed at diagnosis and the karyotype was classified using the International System for Cytogenetic Nomenclature Criteria.
Molecular studies:
Mutation analysis was performed in DNA derived from archived cytogenetic pellets obtained at the time of BM biopsy. KITD816V was evaluated using an allele-specific oligonucleotide polymerase chain reaction assay with fragment analysis performed on an ABI 3130xl genetic analyzer (Applied Bioscience, CA).
Briefly, PCR was used to amplify a fragment containing the mutation site in two separate tubes; one containing a reverse primer complementary to the unmutated sequence and the other containing a reverse primer complementary to the mutated sequence. Each reverse primer was labeled with a fluorescent tag and both tubes contained an identical, non labeled forward primer. Both primer sets amplified a 200 bp fragment that differed only at the mutation site. Samples negative for mutation lacked MgCl 2, 10mM Tris-HCl pH8.3, 50mM KCl). JAK2V617F analysis was performed as previously described.
15
Statistical analyses: Actuarial probability of survival and leukemia-free survival were estimated using the Kaplan-Meier product limit method. Overall survival was defined as the time between diagnosis and death (as a result of all causes) or end of follow-up (censored observations). Leukemia-free survival was calculated from diagnosis to progression to acute leukemia/MCL or end of follow-up. Comparison between KaplanMeier curves were carried out by the log-rank test. Uni-and multi-variate analyses were performed by means of Cox proportional hazards regression model. Expected survival curves were calculated using Hakulinen's cohort method and were matched by age and gender to the US population for the appropriate time period based on diagnosis date. Approximately a third and a quarter of SM-AHNMD and ASM patients, respectively, had significant anemia (Hgb <10 g/dL) and thrombocytopenia (platelets <100 x 10 9 /L), and 51% of SM-AHNMD patients exhibited leukocytosis (p<0.0001).
Fifty-six (16%) patients exhibited prominent eosinophilia (absolute eosinophil count
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From >1500/μL): 31% and 22% with SM-AHNMD and ASM, respectively, versus 3% with ISM (p<0.0001). Relatively few ISM patients exhibited increased levels of serum uric acid (3%), lactate dehydrogenase (4%), bilirubin (11%), or ferritin (18%); or hypoalbuminemia (9%) -in contrast, a 2-3-fold greater proportion of SM-AHNMD and ASM patients displayed these laboratory abnormalities (p≤0.004). Serum tryptase (normal <11.5 ng/mL) was measured in 160 patients (47%) and virtually all (96%) had an elevated level (median 64 ng/mL; range 4 to 2000 ng/mL). A greater proportion of ASM and SM-AHNMD patients exhibited a serum tryptase level ≥200 ng/mL as compared to ISM patients (p=0.009).
ii) Bone marrow histology
Bone marrow histopathologic findings are described in Table 4 . The median BM cellularity for the ISM, ASM, SM-AHNMD, and MCL sub groups was 50% (range 20-100), 75% (30-100), 90% (30-100), and 88% (80-95), respectively (p<0.0001). The median BM MC percentage for the whole group of patients was 10% (range 1-90) and was significantly (p=0.003) higher in MCL (median 75%, range 60-90) compared to ASM (median 13%, range 1-70), SM-AHNMD (median 11%, range 1-70) or ISM (median 10%, range 1-90). All 27 patients with BM blasts ≥5% were diagnosed with SM-AHNMD (9 had refractory anemia with excess blasts-2 [RAEB-2]; 7 chronic myelomonocytic leukemia-1 [CMML-1]; 4 MPN-unclassifiable; 2 RAEB-1; 2 AML-M2; 1 CMML-2; 1 chronic eosinophilic leukemia; and 1 essential thrombocythemia).
iii) Cytogenetic and molecular studies
Cytogenetic data were available for 186 (54%) patients, 37 of whom (20%) had chromosomal aberrations (excluding 5 patients with sole deletion of chromosome Y).
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Recurrent chromosomal abnormalities included trisomy 8, monosomy 7, del(13q), del(5q), trisomy 10, del(20q), trisomy 6, trisomy 19, and trisomy X. Abnormal karyotype was more frequently detected in SM-AHNMD (31%) and ASM (20%), as opposed to ISM (5%) (p=0.0003). All 7 patients with more than one chromosomal abnormality had SM-AHNMD. Fifty-six patients displayed prominent eosinophilia; 52% of 23 patients screened for FIP1L1-PDGFRA and 62% of 34 patients screened for KITD816V carried the mutation, respectively. Eight patients with eosinophilia were screened for FIP1L1-PDGFRA and KITD816V: there were no instances of concomitant presence of these mutations. Archived bone marrow was available in 165 (48%) patients for KITD816V
and JAK2V617F analysis. By allele-specific PCR, KITD816V mutation was detected in 113 patients (68%): ISM 78%, ASM 82%, and SM-AHNMD 60% (p=0.03). The sole MCL leukemia patient who was tested did not harbor this mutation. JAK2V617F mutation was detected (mutant allele burden >1%) in 6 patients (4%); all had SM-AHNMD, including 4 with non-MC lineage myeloproliferative neoplasm. Five of the 6 patients (83%) harbored KITD816V and JAK2V617F mutations concomitantly.
iv) Survival studies and leukemic transformation
After a median follow-up of 20.7 months (range=0-417), 153 (45%) deaths were recorded (26 ISM, 25 ASM, 99 SM-AHNMD, 3 MCL). The median survival of the cohort was 63 months, which is inferior compared to the age-and gender-matched U.S. population ( Figure 1a ). Survival in patients with ISM (median 198 months) was superior (p<0.0001) to that of patients with ASM (median 41 months), SM-AHNMD (median 24 months) or MCL (median 2 months) and not significantly different than that of the control population ( Figure 1b) . Information regarding the cause of death was available for 13 of the 26 (50%) ISM patients: disease progression to ASM (n=3), development of solid tumors (n=3), comorbid cardiovascular conditions (n=3), complications from massive MC mediator release (n=2), acute myeloid leukemia (n=1), and infection (n=1).
Among 21 (6%) cases of leukemic transformation in the overall cohort (18 with AML and 3 MCL), 18 (86%) occurred in the setting of SM-AHNMD, 2 ASM, and 1 ISM (p<0.0001) ( Table 3) .
v) Prognostic factors
In addition to specific diagnosis based on the WHO proposal, other demographic, clinical, and laboratory variables were examined for their prognostic relevance (Table 5) .
In this regard, the pitfalls of considering multiple variables must be kept in mind and certain variables (eg. splenomegaly, hypoalbuminemia; identified by an asterisk in Table   5 ) represent 'B'-or 'C'-findings and are therefore already accounted for in the WHO classification. Multivariable analysis showed a significant and independent association between inferior survival and WHO sub-type (p<0.0001), advanced age (p<0.0001), history of weight loss (p=0.01), anemia (p=0.007), thrombocytopenia (p=0.0008), hypoalbuminemia (p=0.0008) and excess BM blasts (>5%; p=0.004).
Discussion
To our knowledge, the current study is the largest SM series reported in the literature. The clinical findings pertain to an adult SM population with bone marrow histology-confirmed disease that was seen at a tertiary care center. Consequently, extrapolation to a SM population identified primarily on the basis of UP-like skin lesions, or one that includes pediatric patients may not be valid.
Consistent with previous studies, the current cohort had a slight male preponderance; the relatively long duration between onset of symptoms and diagnosis is consistent with absence of UP-like skin lesions in a majority of patients, and also to the referral nature of our practice. The life expectancy of SM patients was shorter relative to age-and gender-matched controls. As initially observed by Travis et al., 2 survival decreased rapidly after diagnosis: to 60% at 3 years, with a subsequent slower decline to 50% at 5 years. Beyond 5 years, the slope of the survival curve was similar to that of the control population. This observation confirms that the excess deaths in SM patients occur within the first 3 (and up to 5) years after diagnosis.
The current study validates the prognostic relevance of the WHO classification for SM. Patients with ISM have a significantly better prognosis in terms of overall survival and leukemia free survival as compared to ASM and SM-AHNMD patients.
Furthermore, the life expectancy of ISM patients was not significantly different from the age-and gender-matched U.S. population for the appropriate time period based on the diagnosis date. Furthermore, leukemic transformation rarely occurs in ISM patients. In contrast, the median survival of SM-AHNMD and ASM patients was 2 and 3.5 years, respectively; MCL patients, not surprisingly, had the poorest prognosis with median survival of 2 months. These data are clinically relevant and serve as a basis for guiding therapeutic decisions in SM patients. It supports the view that, in general, therapy for ISM ought to be symptom directed and potentially immunosuppressive and leukemogenic therapies are best avoided in these patients given the relatively good prognosis and normal life expectancy. 19, 20 For patients with ASM or MCL, or the rare ISM patient with recurrent severe anaphylaxis or syncope not responding to conventional approaches, the goal of therapy is to reduce the systemic MC burden. Published data suggest that interferon-alpha and 2-chlorodeoxyadenosine (2-CdA) have significant inhibitory activity against the malignant MC clone, however both agents are plagued by problems, namely, poor tolerability and uncertainty regarding optimal dose/duration of therapy (IFN-α), or potential mutagenic effects, myelosuppression, and immunosuppression (2-CdA).
21,22
Imatinib is relatively ineffective in KITD816V-positive SM, 23 however may have activity in the rare SM case with other KIT mutations (eg. KITF522C), 24 or in patients with eosinophilia and MC proliferation who harbor the FIP1L1-PDGFRA mutation.
25-27
Preliminary data suggests that dasatinib has limited therapeutic activity in SM, 28, 29 however its role in combination with chemotherapeutic agents is under active investigation.
30,31
In the WHO proposal, 'B'-and 'C'-findings serve as surrogate markers for a high MC burden, and impaired organ function resulting therefrom, respectively, and are used to classify SM patients. Given that 'B'-and 'C'-findings have been defined somewhat arbitrarily (for instance, is Hgb <10g/dL as prognostically relevant as Hgb <8g/dL, or Hgb <normal? Similarly, is presence of pathological fracture as prognostically relevant as hypoalbuminemia?), we conducted a multivariate analysis to identify those variables that may have prognostic relevance within the context of the WHO subgroups. Among the demographic variables, advanced age (≥65 years) was independently associated with shorter survival. Anemia and thrombocytopenia were also independently associated with shorter survival -notably, the threshold for identifying poor risk patients was lower than the corresponding 'C'-findings (defined as hemoglobin <10g/dL and platelet count <100
x 10 9 /L). Weight loss and hypoalbuminemia were also independently associated with In the current analysis, prevalence of KITD816V using a sensitive (0.01%) assay was broadly consistent with published data, 11 considering our use of DNA from unfractionated BM cells. Detection of KITD816V was not significant in the survival analysis; however, the mutation was significantly associated with presence of C-findings (83% vs 64%; p=0.03) and higher BM MC burden (median 13% vs 10%; p=0.01).
JAK2V617F was infrequently detected in SM patients and appeared to be restricted to SM-AHNMD, where it frequently coexisted with KITD816V. In contrast, none of the FIP1L1-PDGFRA-positive patients in our cohort harbored KITD816V, an observation that is consistent with the complete clinical and histologic responses seen with imatinib therapy in these patients.
In summary, we have described the clinical, laboratory, and BM histologic features at presentation in a large cohort of adult SM patients. (5) n/a 13 (32) n/a n/a n/a n/a n/a
Hepatomegaly with functional impairment 31 (9) n/a 11 (27) 20 (14) n/a NS n/a n/a Figure 1a : The observed Kaplan-Meier survival for systemic mastocytosis patients (red) compared with the expected age and gender matched US Population's survival (blue).
Years from Dx For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
